Main content

    Health Information

    Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors) for Erection Problems and Benign Prostatic Hyperplasia

    Phosphodiesterase-5 Inhibitors (PDE-5 Inhibitors) for Erection Problems and Benign Prostatic Hyperplasia



    References

    Citations

    1. Agency for Healthcare Research and Quality (2009). Diagnosis and Treatment of Erectile Dysfunction. Evidence Report/Technology Assessment No. 171 [AHRQ Publication No. 08(09)-E016]. Rockville, MD: Agency for Healthcare Research and Quality. Also available online: http://www.ahrq.gov/downloads/pub/evidence/pdf/erectiledys/erecdys.pdf.

    2. Burnett AL (2012). Evaluation and management of erectile dysfunction. In AJ Wein et al., eds., Campbell-Walsh Urology, 10th ed., vol. 1, pp. 721–748. Philadelphia: Saunders.

    3. Liu L, et al. (2011). Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. Urology, 77(1): 123–130.




    By: Reference Healthwise Staff Last Revised: May 14, 2012
    Medical Review: Reference E. Gregory Thompson, MD - Internal Medicine
    Reference E. Gregory Thompson, MD - Internal Medicine
    Reference Christopher G. Wood, MD, FACS - Urology, Oncology
    Reference Christopher G. Wood, MD, FACS - Urology, Oncology


    This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Reference Terms of Use. Reference How this information was developed to help you make better health decisions.


    Topic Contents